Fat and visceral fat: Time for cardiologists to act against obesity

British Journal of Cardiology

Volumn 12, Issue 4, 2005, Pages

  Lean, Michael E J ^a   Han, Thang S ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; INSULIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; HEALTH HAZARD; HEALTH PROMOTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MEDICAL SPECIALIST; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SUBCUTANEOUS TISSUE; WAIST CIRCUMFERENCE;

EID: 23144444617     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program. Bathesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health. NIH Publication No. 01-3670; May 2001.
2. International Diabetes Federation. www.idf.org.
3. Hillier TA, Pedula KL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care 2001;24:1522-7.
4. Lissner L, Bjorkelund C, Heitmann BL, Seidell JC, Bengtsson C. Larger hip circumference independently predicts health and longevity in a Swedish female cohort. Obes Res 2001;9:644-6.
5. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311:158-61.
6. World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation on obesity. Geneva: WHO. 2000.
7. National Heart, Lung, and Blood Institute (1998). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bathesda, MD: National Institutes for Health: 1998. NIH Publication No. 98-4083.
8. De Bacquer D, De Backer G, Cokkinos D et al. for the EUROASPIRE II Study Group. Overweight and obesity in patients with established coronary heart disease: Are we meeting the challenge? Eur Heart J 2004; 25:121-8.
9. Singh RB, Rastogi SS, Verma R et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992; 304:1015-19.
10. Koertge J, Weidner G, Elliott-Eller M et al. Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicenter Lifestyle Demonstration Project. Am J Cardiol 2003;91:1316-22.
11. Finer N. Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab 2002;16:717-42.
12. James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356:2119-25.
13. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S for the RIO-EUROPE Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-EUROPE study. Lancet 2005;365:1389-97.